9 results about "Cerebral atrophy" patented technology

This invention discloses a low-allergen compound oral liquid for middle-aged and elderly people that protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, combats aging, aids sleep, and prevents Alzheimer's disease. It belongs to the field of food and medicine homology health food technology. The invention uses kudzu root extract, Japanese raisin tree fruit extract, mulberry leaf extract, jujube seed saponins, Acer truncatum seed oil (nervonic acid), blueberry anthocyanins, bitter melon small molecule peptides, wolfberry polysaccharides, γ-aminobutyric acid, and chrysanthemum flavonoids as core active ingredients, refined with a prebiotic system. This invention achieves comprehensive conditioning effects for middle-aged and elderly people through the synergistic action of five pathways: liver protection and metabolism, vascular regulation, anti-oxidation and anti-aging, nerve calming, and brain nerve repair. It simultaneously nourishes and protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, delays aging, improves intractable insomnia, enhances memory, slows brain atrophy, and prevents Alzheimer's disease. This formula strictly avoids eight common allergens, is pure and mild, and contains no irritating additives, making it suitable for long-term use by middle-aged and elderly people with weak constitutions. This product is an oral liquid formulation, with small molecule extraction, strong permeability, rapid absorption, low gastrointestinal burden, stable production process, and high safety. It has extremely high clinical promotion value and industrialization prospects.

The invention discloses application of DDC silencing in an encephalatrophy model, and relates to the field of traumatic brain injury. According to the application, by inhibiting DDC gene expression or protein activity, GSK-3beta kinase mediated Tau protein phosphorylation is regulated and controlled, so that encephalatrophy is relieved or prevented; wherein the encephalatrophy model is an immature brain traumatic brain injury (TBI) after-encephalatrophy model, and DDC silencing is achieved through siRNA, shRNA or antisense oligonucleotide. A gene expression profile after immature brain TBI is analyzed through transcriptome sequencing, DDC is found to be remarkably up-regulated and enriched in a 5-hydroxytryptamine synaptic pathway, an in-vivo experiment proves that DDC expression and Tau phosphorylation level are synchronously increased, an in-vitro experiment shows that DDC silently inhibits GSK-3beta-mediated Tau phosphorylation, and a basis is provided for a DDC-targeted treatment strategy.

The present invention relates to an animal model of cerebellar atrophy, and more specifically, to an animal model in which cerebellar atrophy occurs due to a deletion of the RaRF gene in cerebellar granule cells, neural stem cells of the central nervous system, or neural stem cells of the peripheral nervous system. The animal model of cerebellar atrophy can be used for research on the pathogenesis, diagnosis, prevention, or treatment of cerebellar atrophy, and can be used for screening therapeutic agents for cerebellar atrophy.

The invention discloses a formula of medicinal and edible rice paste capable of tonifying spleen, clearing damp and preventing encephalatrophy. Comprising the following components: 10-20 parts of soybeans, 8-15 parts of small red beans, 6-12 parts of fried coix seeds (fried until the surfaces are light golden yellow and have no burnt spots), 5-10 parts of Chinese yams, 4-8 parts of white poria cocos, 3-7 parts of radix puerariae, 3-6 parts of fried gordon euryale seeds (the frying standard is that the surfaces are slightly burnt and have light burnt fragrance, and the particle size is 2-3mm), 2-5 parts of dried longan, 15-25 parts of millet and 0.5-1.5 parts of shredded dried tangerine peels. The invention belongs to the technical field of medicinal and edible foods, and particularly relates to a medicinal and edible rice paste formula for tonifying spleen, clearing damp and preventing encephalatrophy.

The invention belongs to the technical field of biological medicines, and particularly relates to NA1-albumin nanoparticles as well as a preparation method and application thereof. According to the preparation method disclosed by the invention, NA1 is encapsulated inside and on the surface of albumin nanoparticles through electrostatic interaction between Nerinetide (NA1) and the albumin nanoparticles, so that NA1-albumin nanoparticles are obtained. The encapsulation efficiency of the NA1-albumin nanoparticles to NA1 can reach 80-90%, and the NA1-albumin nanoparticles have the characteristics of natural degradation and pH responsive degradation. The albumin nanoparticles are swallowed by immune cells through complement conditioning, are delivered by using methods such as skull marrow or intracerebral injection, bypass a blood-brain barrier by using a brain marginal immune pathway, improve the delivery efficiency and targeting of NA1 in the brain, have significant effects on reducing the volume of a stroke ischemic region, the volume of an ischemic core region, encephaledema and encephalatrophy, and are suitable for clinical application. The pharmaceutical composition can be used for treating acute brain injury, especially acute ischemic cerebral apoplexy.

The present invention relates to amyloid beta pathology, which is the cause of Alzheimer's disease, and, more specifically, to an amyloid beta pathology risk stratification method using an artificial intelligence model. To this end, provided is the amyloid beta pathology risk stratification method using an artificial intelligence model, comprising steps in which: a dataset related to brain atrophy is extracted from multimodal data (T1, T2 or CT); an artificial intelligence model (140) learns a dataset (100) related to brain atrophy; (S100) the trained artificial intelligence model (140) outputs a predicted probability distribution of amyloid beta-PET positivity and a predicted probability distribution of amyloid beta-PET negativity; (S100) the artificial intelligence model (140) determines an upper threshold and a lower threshold on the basis of the predicted probability distribution of amyloid beta-PET positivity and the predicted probability distribution of amyloid beta-PET negativity; (S120) a control unit stratifies the risk of amyloid beta-PET positivity into a high risk group (151), an intermediate risk group (153) and a low risk group (155) on the basis of the upper threshold and the lower threshold; (S140) a blood biomarker test is performed on the intermediate risk group (153); and (S160) a patient with a positive blood biomarker test result is determined as a patient of amyloid beta-PET positivity, and a patient with a negative blood biomarker test result is determined as a patient of amyloid beta-PET negativity.

The present disclosure provides methods and kits for treating or preventing brain atrophy in a subject. The methods involve administering a sigma-1 receptor agonist and / or a dual modulator of sigma-1 receptor and muscarinic receptor. The brain atrophy can be associated with or related to a neurological disorder.

This prophylactic agent for brain atrophy is intended to be administered to any one subject selected from a normal person, a person who is diagnosed as having mild cognitive impairment, a person who is examined to be deteriorated in cognitive function, a subject who is at a risk of being affected by a neurodegenerative disease, and contains a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) as an active ingredient.

The invention provides inflammation-targeted immunoregulation hydrogel microspheres as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, an injectable mND13 peptide coupled HAMA microsphere (mND13 at HAMA) is designed through a microfluid technology, and the injectable mND13 peptide coupled HAMA microsphere (mND13 at HAMA) can be used for training immune behaviors of microglia for a long time while interacting with a blood vessel microenvironment. As a medium of cell-microenvironment crosstalk, the immunomodulatory factor mND13 is continuously isolated and released, proinflammatory microglial cells are inhibited, blood vessels are protected, and angiogenesis is promoted. This multifunctional microsphere allows for the co-loading of other therapeutic agents in a combination therapy strategy. In an in-vitro cell model and an in-vivo cerebral apoplexy model, the compound system can obviously down-regulate proinflammatory factors (IL-1beta, iNOS, CD86 and IL-6), reduce endothelial cell apoptosis, improve local vascular microenvironment, reduce encephalatrophy volume and improve neurobehavior results of cerebral apoplexy mice.